Central Serous Chorioretinopathy
53
5
5
24
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.5%
4 terminated out of 53 trials
85.7%
-0.8% vs benchmark
4%
2 trials in Phase 3/4
25%
6 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (53)
Central Serous Chorioretinopathy and Micropulse Laser Treatment
Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
OCT in Rare Chorioretinal Diseases
Central Serous Chorioretinopathy Registry and Pachychoroid Observation and Natural History Study
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
Different Doses of vPDT in the Treatment of cCSC
Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Eplerenone Versus PDT: Comparative Study by OCTA
PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
Pilot Study on Deep Learning in the Eye